Table 2.
Diagnosis | Total cohort | Non-users | Usersb | Chronic (35 days)c | Chronic (130 days) |
---|---|---|---|---|---|
Age < 1 year | |||||
Total cohort size | 192,560 (100 %) | 190,597 (100 %) | 1963 (100 %) | 900 (100 %) | 226 (100 %) |
GERD | 22,002 (11.43 %) | 20,478 (10.74 %) | 1524 (77.64 %) | 729 (81.00 %) | 190 (84.07 %) |
GI diagnoses | 16,487 (8.56 %) | 15,788 (8.28 %) | 699 (35.61 %) | 319 (35.44 %) | 80 (35.4 %) |
Neuro-GI disorders | 34,921 (18.14 %) | 34,242 (17.97 %) | 679 (34.59 %) | 340 (37.78 %) | 99 (43.81 %) |
Age 1 to <2 years | |||||
Total cohort size | 220,597 (100 %) | 219,223 (100 %) | 1374 (100 %) | 593 (100 %) | 178 (100 %) |
GERD | 9393 (4.26 %) | 8545 (3.90 %) | 848 (61.72 %) | 466 (78.58 %) | 142 (79.78 %) |
GI diagnoses | 22,539 (10.22 %) | 21,995 (10.03 %) | 544 (39.59 %) | 237 (39.97 %) | 74 (41.57 %) |
Neuro-GI disorders | 14,504 (6.57 %) | 14,106 (6.43 %) | 398 (28.97 %) | 228 (38.45 %) | 81 (45.51 %) |
Age 2–6 years | |||||
Total cohort size | 689,070 (100 %) | 688,227 (100 %) | 843 (100 %) | 248 (100 %) | 108 (100 %) |
GERD | 6035 (0.88 %) | 5745 (0.83 %) | 290 (34.4 %) | 162 (65.32 %) | 76 (70.37 %) |
GI diagnoses | 55,668 (8.08 %) | 55,283 (8.03 %) | 385 (45.67 %) | 140 (56.45 %) | 63 (58.33 %) |
Neuro-GI disorders | 17,967 (2.61 %) | 17,780 (2.58 %) | 187 (22.18 %) | 123 (49.6 %) | 69 (63.89 %) |
Age 7–17 years | |||||
Total cohort size | 1,974,370 (100 %) | 1,971,422 (100 %) | 2948 (100 %) | 554 (100 %) | 156 (100 %) |
GERD | 17,165 (0.87 %) | 16,420 (0.83 %) | 745 (25.27 %) | 287 (51.81 %) | 82 (52.56 %) |
GI diagnoses | 76,965 (3.9 %) | 75,707 (3.84 %) | 1258 (42.67 %) | 305 (55.05 %) | 82 (52.56 %) |
Neuro-GI disorders | 39,536 (2.00 %) | 39,119 (1.98 %) | 417 (14.15 %) | 158 (28.52 %) | 64 (41.03 %) |
GERD symptomatic gastroesophageal reflux, GI gastrointestinal, Neuro-GI neurogastroenterology
aNote that patients could be assigned to multiple diagnostic groups
bThe last three columns are nested. Users includes all chronic users
cChronic users with 130 days’ supply were included in with the chronic users with at least 35 days’ supply